Disc Medicine (IRON) Stock Forecast: StockMap's 2-Week Call
IRON stock forecast: StockMap's model makes no two-week call on Disc Medicine after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 4 of 6 two-week windows on IRON since Aug 21; by chance, a call on the same dates was right 58% of the time.
Disc Medicine last closed at $76.11, -2.40% on the session.
Against the IVW growth benchmark the position is -0.07% over the forecast window.
Disc Medicine's market cap is $3.47B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -13 (too close to call).
Where IRON sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 67%.
36 daily calls for IRON so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Disc Medicine in the 21st percentile on return on equity, where 100 is best.
Disc Medicine is classified under Health Care / Biotechnology.
StockMap tracks Disc Medicine as the 60th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Disc Medicine ranks 122nd of 394 in the group, against a group median of -0.27.